InfuSystem reports record Q3 revenue of $35.3M, up 11% YoY; net income +162%

InfuSystem Holdings, Inc

2024-Q3 EPS reported $0.07 revenue$101,013,000

Net revenue $35.3M (+11% YoY); Patient Services $20.8M (+8%), Device Solutions $14.5M (+15%).
Net income $1.8M (+162%), diluted EPS $0.08; Adj EBITDA $7.9M (+27%), margin 22.3%.
Operating cash flow YTD $12.5M (+91%); liquidity $46.9M as of Sept 30, 2024.
Reaffirms FY2024 guidance: high-single-digit revenue growth, Adj EBITDA margin high-teens.
New partnerships: Smith+Nephew for NPWT and exclusive Chemo Mouthpiece deal with Sanara MedTech.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.